

## The cost effectiveness of REACH-HF and home-based cardiac rehabilitation in the treatment of heart failure with reduced ejection fraction

Taylor, Rod S; Sadler , Susannah ; Dalal, Hasnain M; Warren, Fiona C; Jolly, Kate; Davis, Russell; Doherty, Patrick; Greaves, Colin; Miles , Jackie; Wingham, Jennifer; Hillsdon, Melvyn; Abraham, Charles; Frost, Julia; Singh, Sally J; Hayward , Christopher ; Paul, Kevin; Lang, Chim C; Smith, Karen

*License:*

None: All rights reserved

*Document Version*

Peer reviewed version

*Citation for published version (Harvard):*

Taylor, RS, Sadler , S, Dalal, HM, Warren, FC, Jolly, K, Davis, R, Doherty, P, Greaves, C, Miles , J, Wingham, J, Hillsdon, M, Abraham, C, Frost, J, Singh, SJ, Hayward , C, Paul, K, Lang, CC & Smith, K 2019, 'The cost effectiveness of REACH-HF and home-based cardiac rehabilitation in the treatment of heart failure with reduced ejection fraction: a decision model-based analysis', *European journal of preventive cardiology*.

[Link to publication on Research at Birmingham portal](#)

**Publisher Rights Statement:**

Checked for eligibility 06/02/2019

This is an author-produced, peer-reviewed version of an article forthcoming in European Journal of Preventive Cardiology.  
<https://journals.sagepub.com/home/cpr>

**General rights**

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

**Take down policy**

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Download date: 05. May. 2023

# European Journal of Preventive Cardiology

## The cost effectiveness of REACH-HF and home-based cardiac rehabilitation in the treatment of heart failure with reduced ejection fraction: a decision model-based analysis

--Manuscript Draft--

<b>Manuscript Number:</b>	EJPC-D-18-01031R2
<b>Full Title:</b>	The cost effectiveness of REACH-HF and home-based cardiac rehabilitation in the treatment of heart failure with reduced ejection fraction: a decision model-based analysis
<b>Article Type:</b>	Full Research Paper
<b>Section/Category:</b>	Cardiac Rehabilitation
<b>Keywords:</b>	cardiac rehabilitation, health-related quality of life, heart failure, home-based, cost-effectiveness, decision model
<b>Corresponding Author:</b>	Rod S Taylor University of Exeter Medical School Exeter, UNITED KINGDOM
<b>Corresponding Author Secondary Information:</b>	
<b>Corresponding Author's Institution:</b>	University of Exeter Medical School
<b>Corresponding Author's Secondary Institution:</b>	
<b>First Author:</b>	Rod S Taylor
<b>First Author Secondary Information:</b>	
<b>Order of Authors:</b>	Rod S Taylor
	Susannah Sadler
	Hasnain M. Dalal
	Fiona C. Warren
	Kate Jolly
	Russell C. Davis
	Patrick Doherty
	Colin Greaves
	Jackie Miles
	Jennifer Wingham
	Melvyn Hillsdon
	Charles Abraham
	Julia Frost
	Sally Singh
	Christopher Hayward
	Kevin Paul
	Chim C. Lang
	Karen Smith
<b>Order of Authors Secondary Information:</b>	

<b>Manuscript Region of Origin:</b>	UNITED KINGDOM
<b>Abstract:</b>	<p><b>Background</b></p> <p>The REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) trial found that the REACH-HF home-based intervention resulted in a clinically meaningful improvement in disease-specific health-related quality of life in patients with reduced ejection fraction heart failure (HFrEF). The aim of this study was to assess the long-term cost-effectiveness of the addition of REACH-HF intervention or home-based CR to usual care compared to usual care alone in patients with HFrEF.</p> <p><b>Design and methods</b></p> <p>A Markov model was developed using a patient lifetime horizon and integrating evidence from the REACH-HF trial, a systematic review/meta-analysis of randomised trials, estimates of mortality and hospital admission and UK costs at 2015/6 prices. Taking a UK National Health and Personal Social Services perspective we report the incremental cost per quality-adjusted life-year (QALY) gained, assessing uncertainty using probabilistic and deterministic sensitivity analyses.</p> <p><b>Results</b></p> <p>In base case analysis, the REACH-HF intervention was associated with per patient mean QALY gain of 0.30 and an increased mean cost of £126 compared with usual care, resulting in a cost per QALY of £415. Probabilistic sensitivity analysis indicated a 77% probability that REACH-HF is cost effective versus usual care at a threshold of £20,000 per QALY. Results were similar for home-based CR versus usual care. Sensitivity analyses indicate the findings to be robust to changes in model assumptions and parameters</p> <p><b>Conclusions</b></p> <p>Our analyses indicate that the addition of the REACH-HF intervention and home-based CR programmes are likely to be cost-effective treatment options versus usual care alone in patients with HFrEF.</p>

2<sup>nd</sup> Feb 2019

Dear Handling Editor

**Ref: Ms. No. EJPC-D-18-01031. The cost effectiveness of REACH-HF and home-based cardiac rehabilitation in the treatment of heart failure with reduced ejection fraction: a decision model-based analysis**

Thank you for the further comments on our paper. We have replied to reviewer #4 additional comments and I have emailed our health economist to email an electronic copy of our economic model.

We hope our responses will result in final acceptance of our paper.

Yours sincerely

Prof Rod Taylor on behalf of the co-authors

-----Original Message-----

From: Taylor, Rod

Sent: 02 February 2019 17:34

To: 'susannah sadler' <susisadler@gmail.com>

Cc: 'kvellop@gmail.com' <kvellop@gmail.com>

Subject: FW: Editor Decision - Please Revise

Importance: High

Dear Susie

As requested in 2nd round of peer review of our paper (see below) can I please ask you to email asap an electronic copy of our economic model to reviewer #4 and copy me in. I have copied the reviewer #4 into this email.

Many thanks

Rod

Professor Rod Taylor MSc, PhD

Chair of Population Health Research, Institute of Health and Well Being, University of Glasgow Chair of Health Services Research, Co-Director of Exeter Clinical Trials Unit & NIHR Senior Investigator Institute of Health Research, College of Medicine and Health, University of Exeter

**Ms. No. EJPC-D-18-01031 The cost effectiveness of REACH-HF and home-based cardiac rehabilitation in the treatment of heart failure with reduced ejection fraction: a decision model-based analysis – following 2<sup>nd</sup> round of review**

	Author reply	Revision to manuscript
<b>Reviewer #3</b>		
In my opinion, authors have adequately responded to the points raised by reviewers.	Thank you.	
<b>Reviewer #4</b>		
You addressed the majority of the comments in a satisfactory way. There are some points that need to be clarified, especially concerning the PSA in order for the paper to be of good quality and correspond to the standards of the journal. In total, I reckon that your paper would be of value to the community. I would like to see the model you used. If you do not mind, you can share it with me in my email address (kvellop@gmail.com). Of course, I would abide by the requested confidentiality.	As indicated in our cover letter to editor in the first round of review, we would be pleased to share the model with you. I have copied you into an email to my health economics colleague (Dr Susi Sadler) to request that she forwards an electronic version of our model to you.	None
The key role of cost efficiency in cardiac rehabilitation has been investigated in more recent evidences: You may wish to comment in your revision (eg. 'Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: Results of the FIT@Home study' by Kraal JJ; 'Cost-utility analysis of cardiac rehabilitation after conventional heart valve surgery versus usual care' by Hansen TB)	Our presentation of previous published cost effectiveness for cardiac rehabilitation evidence comes from two recent comprehensive systematic reviews (now cited in the manuscript). We agree that as a home-based strategy, the FIT@home publication is important and we added this.	Text added to discussion section

**The cost effectiveness of REACH-HF and home-based cardiac rehabilitation compared to the usual medical care ~~in the treatment of for~~ heart failure with reduced ejection fraction: a decision model-based analysis**

Rod S. Taylor,<sup>a</sup> Susannah Sadler,<sup>b</sup> Hasnain M. Dalal,<sup>b</sup> Fiona C. Warren,<sup>b</sup> Kate Jolly,<sup>c</sup> Russell C. Davis,<sup>d</sup> Patrick Doherty,<sup>e</sup> Jackie Miles,<sup>f</sup> Colin Greaves,<sup>g</sup> Jennifer Wingham,<sup>a</sup> Melvyn Hillsdon,<sup>h</sup> Charles Abraham,<sup>i</sup> Julia Frost,<sup>a</sup> Sally Singh,<sup>j</sup> Christopher Hayward,<sup>k</sup> Victoria Eyre,<sup>l</sup> Kevin Paul,<sup>m</sup> Chim C. Lang,<sup>n</sup> and Karen Smith,<sup>o</sup> on behalf of the REACH-HF investigators

<sup>a</sup>Institute of Health Research, University of Exeter College of Medicine and Health, Exeter, UK (now Institute of Health and Well Being, School of Medicine, Dentistry & Nursing, University of Glasgow, Glasgow UK); <sup>b</sup>Institute of Health Research, University of Exeter College of Medicine and Health, Exeter, UK; <sup>c</sup>Institute of Applied Health Research, University of Birmingham, Birmingham, UK; <sup>d</sup>Cardiology Department, Sandwell & West Birmingham Hospitals NHS Trust, Birmingham, UK; <sup>e</sup>Department of Health Sciences, University of York, York, UK; <sup>f</sup>Research and Development, Aneurin Bevan University Health Board, St Woolos Hospital, Newport, UK; <sup>g</sup>Institute of Health Research, University of Exeter Medical School, Exeter, UK (now School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham, Edgbaston, UK); <sup>h</sup>Sport and Health Sciences, University of Exeter, Exeter, UK; <sup>i</sup>Institute of Health Research, University of Exeter Medical School, Exeter, UK (now School of Psychological Sciences, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Parkville, Victoria 3010, Australia), UK; <sup>j</sup>Centre for Exercise and Rehabilitation Science, University Hospitals of Leicester NHS Trust, Glenfield Hospital, Leicester, UK; <sup>k</sup>Peninsula Clinical Trials Unit, University of Plymouth, Plymouth, UK; <sup>l</sup>Re:Cognition Health, London, UK; <sup>m</sup>REACH-HF Patient and Public Involvement Group, c/o Research, Development & Innovation, Royal Cornwall Hospitals NHS Trust, Truro, UK; <sup>n</sup>School of Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK; <sup>o</sup>School of Nursing and Health Sciences, University of Dundee, Dundee, UK.

**Previous presentations:** none

**Disclaimers:** none

**Address for correspondence:** Professor Rod Taylor MSc, PhD, Chair of Health Services Research, Director of Exeter Clinical Trials Unit & NIHR Senior Investigator, Institute of Health Research, University of Exeter Medical School, South Cloisters, St Lukes Campus, Heavitree Road, Exeter, EX1 2LU, England, UK; Office: +44 (0)1392 726053; Mobile: + 44 (0)7968 152537; Email: [r.taylor@exeter.ac.uk](mailto:r.taylor@exeter.ac.uk)

**Funding:** This work was supported by the United Kingdom's National Institute for Health Research (NIHR) Programme Grants for Applied Research [grant number RP-PG-1210-12004]. Professors Taylor and Britten are part-funded by the National Institute for Health Research (NIHR) Collaboration for Peninsula Leadership in Applied Health Research and Care. Professor Jolly is part-funded by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care (CLAHRC) West Midlands. Professor Britten is part-funded by the NIHR CLAHRC South West Peninsula. Professor Singh is supported by NIHR CLARCH East Midlands. The funders' peer-review process informed the trial protocol. The sponsor of the trial had no role in trial design, data collection, data analysis, data interpretation, or writing of the report. The views expressed in this publication are those of the authors and not necessarily of the NIHR or United Kingdom's Department of Health and Social Care.

**Word count:** 4979 (including references, tables and figures)

## Abstract

**Background:** The REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) trial found that the REACH-HF home-based [cardiac rehabilitation \(CR\)](#) intervention resulted in a clinically meaningful improvement in disease-specific health-related quality of life in patients with reduced ejection fraction heart failure (HFrEF). The [aims](#) of this study ~~were~~[was](#) to assess the long-term cost-effectiveness of the addition of REACH-HF intervention or home-based CR to usual care compared to usual care alone in patients with HFrEF.

**Design and methods:** A Markov model was developed using a patient lifetime horizon and integrating evidence from the REACH-HF trial, a systematic review/meta-analysis of randomised trials, estimates of mortality and hospital admission and UK costs at 2015/6 prices. Taking a UK National Health and Personal Social Services perspective we report the incremental cost per quality-adjusted life-year (QALY) gained, assessing uncertainty using probabilistic and deterministic sensitivity analyses.

**Results:** In base case analysis, the REACH-HF intervention was associated with per patient mean QALY gain of 0.~~230~~ and an increased mean cost of £~~400426~~ compared with usual care, resulting in a cost per QALY [gained](#) of £1,720,445. Probabilistic sensitivity analysis indicated a ~~78~~7% probability that REACH-HF is cost effective versus usual care at a threshold of £20,000 per QALY [gained](#). Results were similar for home-based CR versus usual care. Sensitivity analyses indicate the findings to be robust to changes in model assumptions and parameters

**Conclusions:** Our [cost-utility](#) analyses indicate that the addition of the REACH-HF intervention and home-based CR programmes are likely to be cost-effective treatment options versus usual care alone in patients with HFrEF.

**Key words:** cardiac rehabilitation, health-related quality of life, heart failure, home-based, cost-effectiveness, decision model



## Introduction

Heart failure with reduced ejection fraction (HFrEF) represents a major health issue and is associated with considerable morbidity and mortality. HF as primary diagnosis accounts for 1-2% of the annual healthcare budget in Europe and USA [1]. The global ~~cost-economic~~ burden of HF is estimated at \$US108 billion per annum with hospital admission being a key economic driver [2].

Systematic reviews and meta-analyses of cardiac rehabilitation (CR) for HF have shown improvements in health-related quality of life (HRQoL), reductions in re-hospitalisations and demonstrated potential cost-effectiveness [3,4]. This existing evidence is based solely entirely for on hospital (or centre)-based CR programmes and the economic evaluation data is limited in both quantity and quality [3,4].

In spite of national and international guidelines recommending CR for HF [5-7], less than 20% of HF patients in the UK are referred to CR and less than 15% currently participate in CR [8-10], prompting calls for alternative more accessible models of CR provision [8]. REACH-HF (Rehabilitation EnAblement in CHronic Heart Failure) is a home-based CR programme delivered over a 12-weeks by a trained healthcare professional for patients and their caregivers. Uniquely the REACH-HF intervention has been co-developed with patients, caregivers, and clinicians to include core components of comprehensive CR, i.e., education and psychological support, in addition to exercise training [11]. The REACH-HF randomised controlled trial compared the addition of REACH-HF intervention to usual care with usual care alone in patients with HFrEF across four UK sites [12]. At 12-months, the trial found - that the REACH-HF intervention led to a statistically significant and clinically meaningful improvement in HRQoL with a reduction in total Minnesota Living with Heart Failure Questionnaire score of -5.7 points (95% confidence interval: -10.6 to -0.7) and a non-significant reduction in the number of patients experiencing one or more hospital admissions (odds ratio: 0.56, 95% CI: 0.13 to 2.33). [13]. Having estimated the average cost of REACH-HF delivery at £418 per patient [13], we sought to assess if the REACH-HF intervention is likely to be cost-effective for healthcare payers over the long-term.

We report the results of a model-based cost-effectiveness analyses that extrapolates the findings of REACH-HF trial to estimate the long-term cost-effectiveness of REACH-HF intervention. We also report the long-term cost-effectiveness of home-based CR based on a meta-analysis of randomised trials.

## Methods

This analysis was reported in accord with the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement [14] and the reference case of the UK National Institute for Health and Care Excellence (NICE) [15]. The analyses were conducted from the perspective of the UK NHS and Personal Social Services. We estimated the cost-effectiveness of REACH-HF plus usual care versus usual care alone and home-based CR plus usual care versus usual care alone, based on the estimated incremental cost per quality-adjusted life-years (QALY)- a cost-utility analysis.

## Study Population

Data were used from the REACH HF trial [13] where participants with HFrEF were recruited from primary and secondary care in 4 UK centres during 2015–2016 and were randomly assigned to the REACH-HF intervention plus usual care or usual care alone (current standard therapy in the UK for most patients with HF) [12]. In the UK, only a minority of patients with HF receive CR and usual care in this trial was a no CR approach that included medical management according to national and local guidelines, including specialist HF nurse care [13]. Details of REACH-HF intervention are presented elsewhere [12,13].

## Model Structure

Consistent with the economic evaluation literature in HF [16], a Markov cohort model (eFigure 1) was developed that captured the impact ~~on~~<sup>of</sup> hospital admissions, and a related increase in the mortality rate, for people with HF. In this case a cohort Markov model was considered appropriate since this estimates the average effect of the intervention on morbidity, mortality, cost and HRQoL. The model uses a lifetime horizon (follows patients from a starting age of 78 to age 100) and costs and QALYs were discounted at 3.5% [15]. The model consisted of three primary health states: (1) HF with no HF-related hospital admission, (2) HF with HF-related hospital admission, and (3) death. The model uses a one-month cycle length, in order to capture the effects of hospital admission events which are short term events but may recur several times in a year. Tunnel states are used in the model to reflect an increased mortality risk in the period (1 to 38 months) after hospital admission/discharge. Patients begin in a stable HF health state (HF with no HF-related hospitalisation). From this state, patients can either remain in the same state, or experience an HF-related hospitalisation or death. If the patients experience an HF-related hospitalisation, they automatically progress to the first of 38 post-hospitalisation tunnel states, where they will progress one state each month until month 38 post-hospitalisation, when they will return to the HF with no HF-related hospitalisation state. During the tunnel states, patients can also experience an additional hospitalisation or death at any time. ,and

~~the model uses the patient lifetime duration to estimate and compare the costs and QALYs for patients receiving REACH-HF or home-based CR.~~ The model was developed in Microsoft Excel and programmed in Visual Basic for Applications.

### **Model inputs**

The model parameters and assumptions about transitions between health states are outlined in Table 1.

#### **CR Effectiveness**

We used data from REACH-HF trial for the difference in risk of hospital admission (odds ratio: 0.56, 95% CI: 0.13 to 2.33) [13]. We also undertook a meta-analysis that combined REACH-HF trial data with two other randomised trials of home-based CR [versus no CR usual care](#) [17,18] to estimate the pooled risk of hospital admission following home-based CR compared to usual care (odds ratio: 0.70, 95% CI: 0.27 to 1.60) (see [eFigure 1 for meta-analysis forest plot and methodology](#)). This reduction in risk was assumed to last for four years from the start of the model, after which hospital admission rates are assumed to return to baseline. We assessed the impact on estimates of cost-effectiveness of variations in this assumption using sensitivity analyses.

#### **Hospital Admissions**

We applied hospital admission data for HF specific admissions from a UK cohort study reflective of a UK primary care setting, with patients experiencing both first and subsequent hospital admissions [19] (see Table 1). In sensitivity analyses, we tested the robustness of model outcomes to changes in hospital admission rates, using data from the UK Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS) trial [20], which provided a lower estimate of admission rates (10% HF-related admissions; 20% all cause admissions per annum), and a meta-analysis of randomised trials [21] reporting relatively high admission rates (34% HF-related admissions; 85% all cause admission per annum). We used the same admission rate for all patients in the model irrespective of age and previous admissions.

#### **Mortality**

Survival parameters in the model are based on a recently published analysis of UK mortality rates in The Health Improvement Network (THIN) dataset, 1998-2012 [22], a retrospective cohort of 54,313 HF patients aged over 45. In a sensitivity analysis, we applied the overall survival reported by Mohiuddin et al [23] for patients in another large UK cohort, who had already experienced a hospital admission for HF and therefore are expected to have a worse prognosis. [This study showed increased risk for time since admission in people 0-1 months.](#)

1-3 months, 3-6 months, 6-12 months, 12-24 months and 24-38 months after admission. The reported hazard ratios were applied in the model.

Mortality rates have been shown to vary with hospital admission and after discharge both in trials [24] and in the wider UK HF population, ~~more generally~~ [25] with those in hospital and closer to discharge having higher death rates. Following the approach of Thokala et al [26], we reflected this in the model using the hazard ratio for all-cause mortality reported by Solomon et al [24] for patients within 1 to over 24 months from discharge for their HF hospital admission. For hospital mortality, we derived ~~an additional~~ hazard ratio for survival for patients in hospital compared to within 30 days of discharge, from the UK HF Audit [25], which reports outcomes from data on more than 73% of all English and Welsh HF admissions. We calibrated the baseline mortality rate so that the overall survival curves generated by the model matched the survival curves based on parameters taken from the THIN analysis [21]. We conservatively assumed that the hazard ratio of death for subsequent hospital admissions was the same as for the first hospital admission. We assumed that survival followed an exponential curve which has previously been shown to provide a good fit in this population [23,27].

### **Costs**

Costs were included in pounds sterling using the 2015/16 price year. The following costs were considered: (i) home-based CR, (ii) costs associated with HF hospital admission, (iii) costs associated with other cause hospital admission, and (iv) primary and secondary usual health care costs (excluding hospital admission) associated with HF (see Table 1). For intervention cost we use the UK NHS tariff for CR of £477/patient [28] and the estimated cost for delivery of the REACH-HF intervention of £418/patient [13]. This cost was applied to all patients at the start of the model. Ongoing costs for usual care for HF, primary care, secondary care, Accident & Emergency department attendances and drug costs, are included for time spent in the HF non-hospital admission state (£815/patient per year), informed by UK national data for HF and the THIN dataset, a large UK HF cohort study [22]. The cost for hospital admission is based on data from the English NHS National Schedule of Reference Costs 2015/16 [28], for HF hospital admission we use a weighted average cost of a single hospital stay for the health resource groups (HRGs) EB03A to D. The cost of non-HF hospital admissions is a background cost in each cycle of the model, where patients are alive with HF. We discounted costs and QALYs at an annual rate of 3.5% in accord the NICE reference case [15].

### **Health state values**

We calculated QALYs by multiplying the health value for the state by the time spent in that state. We use data from Systolic Heart failure treatment with the inhibitor ivabradine Trial (SHIFT) to inform health state values, applying a health state value of 0.736 for the HF health state, and a reduction (decrement) of 0.084 where people experience a HF related hospital admission [30]. For non-HF hospital admissions, we apply a decrement of 0.032 for events. The impact of hospital events on health state values is applied for the one-month cycle of hospital admission after which individuals were assumed to return to baseline values. Data from the SHIFT trial, was considered to be the most appropriate for our model given the reporting of EQ-5D data for the HF state and separately for a HF specific hospital admission.

### Analysis

We present deterministic estimates of the cost per QALY gained and use probabilistic sensitivity analysis (PSA) and the incremental net monetary benefit (iNMB) approach [31,32] to address uncertainty around the results. The iNMB approach uses parameters representing the maximum amount that the Payer (i.e. NHS) is 'willing to pay' to gain one QALY. We conservatively used the lower NICE threshold value of £20,000 per QALY gained in calculating iNMB [15]. An iNMB value > 0 would indicate that the intervention (home based CR) is cost-effective. The cost-effectiveness acceptability curve (CEAC) ~~to~~ demonstrates s how the willingness-to-pay threshold affects the probability that the intervention is considered cost-effective [32]. Monte Carlo simulation was used to draw a randomly selected estimate of each model parameter from the distributions described in Table 1 and to calculate the iNMB. Beta distributions represent the uncertainty in the probability parameters (mortality, hospital admission) and parameters for health state values because these values are typically bounded at zero and one. Log-normal distributions were used to estimate uncertainty in hazard rates and ratios. We used 5,000 iterations to empirically estimate the uncertainty surrounding the mean iNMB.

The key element of structural uncertainty identified was ~~the use of increasing HF-related mortality rates during admission and after discharge from hospital~~ for an HF-related event. This mechanism allows any reductions in admission rate brought about by the intervention to reduce overall mortality in the cohort, with related cost savings and QALY gains estimated. To test how sensitive the results are to the inclusion of this element of model structure we included a sensitivity analysis which uses a base mortality rate (from the THIN cohort [22]) for all patients at all times, regardless of hospital admission (SA1).

In addition, we included further deterministic analyses to test how sensitive the results were to the choice of parameter as follows: the lowest hospital admission rate from trials identified as sources of HF-specific admission (0.88% probability of admission per month, based on

the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS) trial [20] (SA2); the higher hospital admission rate from a large meta-analysis of trials (2.83% probability of admission per month [21] (SA3); survival based on previously-admitted patients in the large combined data in Hospital Episode Statistics (HES) and Office of National Statistics (ONS) dataset [23] (SA4); lower mean intervention cost of £204/patient, based on the lower bound of the 95% confidence interval around estimated cost for REACH-HF intervention (SA5); higher mean intervention cost of £730, based on the upper bound of the 95% confidence interval around estimated cost for the REACH-HF intervention [13]; and assumption for home-based CR effect duration, at 2 years (SA7).

## Results

### **Base-case analysis**

#### REACH-HF intervention

Over the HFrEF patient lifetime, compared to usual care alone, the addition of REACH HF intervention was more costly (mean £~~400426~~/patient) and more effective (mean QALY 0.~~239~~) with an estimated incremental cost effective ratio of £~~1720445~~/QALY (Table 2). There was a 78~~7~~% probability that REACH-HF was cost-effective at willingness to pay threshold of £20,000/QALY gained (eFigure 3a).

#### Home-based CR

The estimated mean gain in QALYs for home-based CR compared to usual care was 0.~~1629~~, and the estimated mean incremental cost is £~~383206~~/patient over the lifetime, giving an estimated incremental cost ratio of per £~~2,4134,029~~ per QALY (Table 2). There was 73~~5~~% probability that home-based CR was cost-effective compared to usual care, at £20,000/QALY gained (eFigure 3b).

### **Sensitivity analyses**

Sensitivity analyses (eTables 1a and 1b) indicate the base case analyses to be robust and not sensitive to changes in key structural assumptions in the modelling framework or key input parameters (i.e. mortality effect of hospital admission, probability of hospital admission, probability of mortality, home-based CR, duration of treatment effect) for both REACH-HF and home-based CR. Removing the increase in risk of mortality after hospital admission (SA1) resulted, in home-based CR dominating usual care, with a reduction in costs (cost saving) and no difference QALYs. In this scenario, although QALY gains are reduced, the costs associated with home-based CR also reduce due to the absence of an extended period of life expectancy and the absence of the additional costs associated with extending lives in the home-based CR group.

## Discussion

Our estimates suggest that the addition of REACH-HF intervention home-based CR to usual care was cost-effective compared to usual care alone in patients with HFrEF at a cost of £1730445/QALY and a 787% likelihood of being cost-effective at the willingness to pay threshold of £20,000 per QALY gained used by policymakers in UK and many developed health-care economies [15,33]. Our cost-effectiveness estimates for other home-based CR programmes were similar. Our results were mainly driven by a reduction in HF-related hospitalisations with CR.

Two recent systematic reviews of cost-effectiveness of CR have been published [4,34]. To the best of our knowledgeBased on the results of these reviews, this is first published full economic evaluation of a comprehensive a specific home-based programme (REACH-HF) and home-based CR programmes more broadly in patients with HF. However, our findings are consistent with previously economic evaluations in HF comparing centre-based CR to no CR control [4]. Using extrapolated outcome survival data from a single centre randomised controlled trial, Georgiou and colleagues reported an incremental cost-effectiveness ratio of US\$2500 per life year gained for exercise training programme at a 10-year time horizon based on US healthcare perspective [354]. Using a variety of modelling assumptions and data at 2.5 years follow up from the large HF-ACTION trial undertaken across 82 centres across United States, Canada, and France, Reed et al estimated that the cost-effectiveness of exercise training could vary from dominant (cost saving and more QALYs gained) to US\$43,141/QALY [366]. Based on data from exercise-based CR programme in Colombia, using modelling Rincón et al estimated an incremental cost per QALY of US\$1,065/QALY at 5 years [376]. Finally, a Markov model-based analysis by Kühr et al reported a cost per QALY of 29,498 international dollars for a hypothetical cohort of HF patients attending outpatient CR programme from the perspective of the Brazilian Public Healthcare System over a 10-year time horizon [387]. Notwithstanding the challenge of directly comparing costs across international jurisdictions and whilst these incremental cost effectiveness ratios vary in their magnitude, they have broadly been interpreted by study authors as demonstrating CR to be a cost-effective strategy in patients with HFrEF.

Although not recruiting HF patients, the recently published FIT@Home study also showed home-based CR can be a cost-effective strategy [39]. This study randomised 90 low to moderate risk patients following an acute coronary syndrome or revascularisation to three months of either home-based training with telemonitoring guidance or centre-based training. Average healthcare costs were lower in the home-based group (€437 per patient) and had probability of being cost-effective of 97% and 75% at willingness-to-pay of €0 and €100,000 per QALY, respectively.

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight

Formatted: Highlight



### **Strengths and limitations**

This study uses sed cost and outcome data from a high quality multicentre randomised controlled trial of REACH-HF in patients with HFrEF with multiple comorbidities reflective of the clinical setting [13]. The use of Markov modelling overcomes the limitations of a within trial economic evaluation, allowing the modelling of costs and outcomes over the longer term of patient lifetime and the assessment of the long-term cost effectiveness beyond the trial period. The use of longer time-horizon is also more compatible with the chronic nature of HF and in accord with NICE methodology guidance [15]. We use high quality data on mortality from a large cohort study consistent with the setting for our economic analysis. Given the variation of hospital admission data, we use a UK dataset in our base case analysis. However, use was made of alternative data sources ~~were used~~ in sensitivity analyses. A key limitation was that the REACH-HF trial was not powered to detect differences in hospitalisations between arms. However, we sought to overcome this by undertaking a meta-analysis where we included data from two other randomised trials that tested different versions of home-based CR. Furthermore, our probabilistic sensitivity analysis explicitly took account of the uncertainty in the data inputs to the model. Nevertheless, ~~that the overall number of hospitalisations was low (30 events), we acknowledge the need for additional future trials of CR need to consistently collect ing and report this the outcome of patient hospitalisation.~~ Furthermore, our probabilistic sensitivity analysis explicitly took account of the uncertainty in the data inputs to the model. We used a simple Markov modelling approach, and whilst this approach is consistent with the wider literature on economic models in HF, we acknowledge it assumes no additional impact from multiple admissions. Whereas in real life patients may suffer from worsening HRQoL after further subsequent hospital stays. This conservative assumption may have led us to have underestimated the cost-effectiveness of REACH-HF and home-based CR. We use HF-related hospital admissions as the main event of interest in the assessment of home-based CR. The absence of any specific modelling of effects on other (non-HF specific) cause of hospital admissions may be a limitation of the modelling, although is also likely to a conservative assumption as CR may positively impact on the risk of admissions due to other cardiovascular related events, such as myocardial infarction or stroke.

### **Clinical implications**

This cost-utility analysis indicates that the REACH-HF intervention and home-based CR programmes are likely to be cost-effective for patients for HFrEF. These economic results have considerable policy relevance given current low levels of uptake of CR for HF across international healthcare systems [4038]. In order to improve CR participation there have been calls for the development of CR programmes that provide an alternative to supervised

Formatted: Highlight

outpatient programmes, such as home-based programmes [8,9,4139]. The results of this analysis are therefore timely and show that home-based CR programmes provide a cost-effective alternative use of healthcare resources. The systematic review of home versus centre-based CR by Wong et al concluded that as costs and outcomes of home-based versus supervised centre-based CR were no different, the choice of the mode of delivery (home- versus centre-based) should be left to healthcare providers and patients [426]. This is further reinforced by the recently updated UK clinical guidelines for the management of HF that patients, which recommend that patients should be offered CR “in a format and setting (at home, in the community or in the hospital) that is easily accessible for the person” [7].

Formatted: Highlight

Formatted: Highlight

## Conclusion

Over the lifetime of the HFREF patient, our [cost-utility](#) analyses suggest that REACH-HF and home-based CR are cost-effective treatment options in the setting of the United Kingdom health service. These findings should encourage healthcare providers and purchasers to fund home-based CR programmes to improve access and promote participation in CR for people with HF and thereby improve the health-related quality of life and morbidity of this population.

**Author contribution:** HMD, RST, KJ, RCD, PD, JM, JW, NB, CGreaves, CA, and SSingh obtained the funding for the study. SSadler undertook the economic modelling analysis, RST undertook the meta-analysis, and both jointly drafted the manuscript. All authors commented on the manuscript and agreed the final version

**Formatted:** Font: Bold

**Acknowledgements:** We thank all REACH-HF study participants, facilitators, clinicians, researchers, and administrators who contributed data or their expert opinion and advice to the study in Birmingham, Cornwall, Exeter, Gwent, York, Heart Manual Department NHS Lothian (Carolyn Deighan, Louise Taylor and Jenny Elliott), Peninsula Clinical Trials Unit, Royal Cornwall Hospitals Trust (Research, Development and Innovation and Clinical Chemistry departments), PPI Advisory Group (Kevin Paul (Chair)), Programme Steering Committee (Martin Cowie (Chair), Graham Dunn, Suzanna Hardman, Roger Boyle, and Liz Clark), Data Monitoring Committee (Ann Dorthe-Zwisler (Chair), Alan Montgomery, and Gill Furze), and independent adjudicators (Iain Squire, Sern Lim, and Paco Leyva).

**Declaration of conflict of interests:** There are no other declared potential conflicts of interest with respect to research, authorship, and/or publication of this article.

**Data sharing:** No additional data are available.

## References

1. Liao L, Allen LA, Whellan DJ. Economic burden of heart failure in the elderly. *Pharmacoeconomics*. 2008;26:447-62.
2. Cook C, Cole G, Asaria P, Jabbour R, Francis DP. The annual global economic burden of heart failure. *Int J Cardiol*. 2014;171:368-76.
3. Taylor RS, Sagar VA, Davies EJ, et al Exercise-based rehabilitation for heart failure. *Cochrane Database Syst Rev*. 2014 Apr 27;(4):CD003331.
4. Shields GE, Wells A, Doherty P, et al. Cost-effectiveness of cardiac rehabilitation: a systematic review. *Heart*. 2018;104:1403-1410.
5. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *J Am Coll Cardiol*. 2013; 62:e147-e239.
6. Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail*. 2016; 18: 891–975.
7. National Institute for Health and Care Excellence. *Chronic heart failure in adults: diagnosis and management* (NICE guideline NG106) 2018. <https://www.nice.org.uk/guidance/ng106>
8. Golwala H, Pandey A, Ju C, et al. Temporal trends and factors associated with cardiac rehabilitation referral among patients hospitalized with heart failure: Findings from Get With The Guidelines-Heart Failure Registry. *J Am Coll Cardiol*. 2015; 66: 917-926.
9. Bjarnason-Wehrens B, McGee H, et al. Cardiac rehabilitation in Europe: Results from the European Cardiac Rehabilitation Inventory Survey. *Eur J Cardiovasc Prev Rehabil*. 2010; 17: 410-418.
10. National Audit of Cardiac Rehabilitation (NACR) Annual Statistical Report 2017. <https://www.bhf.org.uk/informationsupport/publications/statistics/national-audit-of-cardiac-rehabilitation-annual-statistical-report-2017>
11. Greaves CJ, Wingham J, Deighan C, et al. Optimising self-care support for people with heart failure and their caregivers: Development of the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) intervention using intervention mapping. *Pilot Feasibility Stud*. 2016;2:37.
12. Taylor RS, Hayward C, Eyre V et al. The clinical effectiveness and cost-effectiveness of the Rehabilitation Enablement in Chronic Heart Failure (REACH-HF) facilitated

self-care rehabilitation intervention in heart failure patients and caregivers: Rationale and protocol for a multicentre randomised controlled trial. *BMJ Open* 2015; 5: e009994.

13. Dalal HM, Taylor RS, Jolly K, et al. The effects and costs of home-based rehabilitation for heart failure with reduced ejection fraction: The REACH-HF multicentre randomized controlled trial. *Eur J Prev Cardiol.* 2018 Oct 10:2047487318806358. doi: 10.1177/2047487318806358.
14. Husereau D, Drummond M, Petrou S, et al Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *BMJ.* 2013;346:f1049.
15. NICE. *Guide to the Methods of Technology Appraisal.* London: National Institute for Health and Clinical Excellence, 2013~~08~~. Available from: <https://www.nice.org.uk/process/pmg9/chapter/foreword> [Accessed ~~October 20~~January 10th, 201~~98~~].
16. Goehler A, Geisler BP, Manne JM, et al. Decision-analytic models to simulate health outcomes and costs in heart failure: a systematic review. *Pharmacoecon.* 2011;29: 753-769.
17. Jolly K, Taylor RS, Lip GY et al. A randomized trial of the addition of home-based exercise to specialist heart failure nurse care: the Birmingham Rehabilitation Uptake Maximisation study for patients with Congestive Heart Failure (BRUM-CHF) study. *Eur J Heart Fail.* 2009;11: 205-213.
18. Passino C, Severino S, Poletti R, et al. Aerobic Training Decreases B-Type Natriuretic peptide expression and adrenergic activation in patients with heart failure. *J Am Coll Cardiol.* 2006;47:1835-1839.
19. Cowie MR, Fox KF, D. Wood DA, et al. Hospitalization of patients with heart failure: a population-based study. *Eur Heart J.* 2002;23: 877-885.
20. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. *N Engl J Med.* 2011;364: 11-21.
21. Kotecha D L, Manzano H, Krum G, et al. Effect of age and sex on efficacy and tolerability of beta blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. *BMJ.* 2016; 353: i1855
22. Taylor CJ, Ryan R, Nichols L, et al. Survival following a diagnosis of heart failure in primary care. *Fam Pract.* 2017; 34:161-168.
23. Mohiuddin SB, Reeves M, Pufulete R. et al. Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. *BMJ Open.* 2016;6:e014010.

24. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. *Circulation* 2007;116:1482-1487.
25. Donkor A, McDonagh T Hardman S. *National Heart Failure Audit 2015-2016*. NICOR. London, UCL Institute of Cardiovascular Science. EBM DataLab, 2017. OpenPrescribing.net. Univ of Oxford.
26. Thokala P, HBaalbaki H, Brennan A, et al. Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. *BMJ Open*. 2013;3:e003250.
27. Hobbs FD, Roalfe AK, R. Davis RC, et al. Prognosis of all-cause heart failure and borderline left ventricular systolic dysfunction: 5 year mortality follow-up of the Echocardiographic Heart of England Screening Study (ECHOES). *Eur Heart J*. 2007;28:1128-1134.
28. Strategic Commissioning Development Unit. Cardiac rehabilitation: *Costing tool guidance*. London: Department of Health, 2010.
29. Department of Health. *NHS reference costs 2015 to 2016*. Department of Health. 2016.
30. Kansal AR, Cowie M, Kielhorn A, S. Krotneva, A. et al. Cost-effectiveness of ivabradine as a treatment for systolic chronic heart failure in the United States. *J Am Heart Assoc*. 2016;5. pii: e003221
31. Briggs A, Sculpher M, Claxton K. *Decision Modelling for Health Economic Evaluation*. Great Clarendon Street, Oxford., Oxford University Press. 2006
32. Fenwick E. Byford S. A guide to cost-effectiveness acceptability curves. *Br J Psychiat*. 2005;187:106-108.
33. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. *Brit Med J*. 2004;329:224-7.
34. Edwards K, Jones N, Newton J, et al. The cost-effectiveness of exercise-based cardiac rehabilitation: a systematic review of the characteristics and methodological quality of published literature. *Health Econ Rev*. 2017;7:37.
35. Georgiou D, Chen Y, Appadoo S, et al. Cost-effectiveness analysis of long-term moderate exercise training in chronic heart failure. *Am J Cardiol*. 2001;87:984-8.
36. Reed SD, Whellan DJ, Li Y, et al. *Economic evaluation of the HF-ACTION (Heart Failure: A Controlled Trial Investigating Outcomes of Exercise Training) randomized controlled trial: an exercise training study of patients with chronic heart failure. Circ Cardiovasc Qual Outcomes*. 2010;3:374-81.

Formatted: Highlight

Formatted: Font: Italic, Highlight

Formatted: Highlight

Formatted: Font: Italic

Formatted: Font: Italic

36-37. Rincón M, Rojas MX, Rodríguez Romero VA, et al. Economic evaluation of exercise-based cardiac rehabilitation programs for chronic heart failure patients in Colombia. *J Cardiopulm Rehabil Prev*. 2016;36:12-9.

38. Kühr EM, Ribeiro RA, Rohde LE, et al. Cost-effectiveness of supervised exercise therapy in heart failure patients. *Value Health*. 2011;14(5 Suppl 1):S100-7.

37-39. Kraal JJ, Van den Akker-Van Marle ME, Abu-Hanna A, et al. Clinical and cost-effectiveness of home-based cardiac rehabilitation compared to conventional, centre-based cardiac rehabilitation: Results of the FIT@Home study. *Eur J Prev Cardiol*. 2017;24:1260-1273.

38-40. Ades PA, Keteyian SJ, Wright JS, et al. Increasing cardiac rehabilitation participation from 20% to 70%: a road map from the Million Hearts Cardiac Rehabilitation Collaborative. *Mayo Clin Proc*. 2017;92:234-242.

39-41. Dalal HM, Doherty P, Taylor RS. Cardiac rehabilitation. *BMJ*. 2015;351:h5000.

40-42. Wong WP, Feng J, Pwee KH, et al. A systematic review of economic evaluations of cardiac rehabilitation. *BMC Health Serv Res*. 2012;12:243.

41-43. Michel A, Martín-Pérez M, Ruigómez A, et al. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. *Eur J Heart Fail*. 2015;17:205-13.

42-44. Curtis L, Burns A. *Unit Costs of Health & Social Care 2016*. Personal Social Services Research Unit. The University of Kent. 2016

45. Joint Formulary Committee. *British National Formulary*. London. 2017

43-46. Long L, Mordi IR, Bridges C, Sagar VA, Davies EJ, Coats AJS, Dalal H, Rees K, Singh SJ, Taylor RS. Exercise-based cardiac rehabilitation for adults with heart failure. *Cochrane Database Syst Rev* 2019, Issue 4 (in press).

Formatted: Highlight

Formatted: Font: Italic, Highlight

Formatted: Highlight

Formatted: Font: 11 pt, Italic





Table 1. Model parameters and assumptions

Parameter	Base case value (mean)	Probabilistic distribution	Standard error	Source
Mortality				
Monthly probability of death*	0.650%	Beta		[22]
RR of death in hospital compared to 30 days of discharge	1.5	Fixed		[25]
HR of mortality rate ≤1	6.18	Lognormal	1.1364	[24]
by months since >1	4.39	Lognormal	1.1225	
discharge >3	3.54	Lognormal	1.1150	
>6	3.11	Lognormal	1.0978	
>12	2.46	Lognormal	1.0948	
>24	1.93	Lognormal	1.1450	
Hospital admission				
Monthly probability of HF admission	2.04%	Beta		[19]
Monthly probability of other cause admission	1.97%	Beta		[19]
Average length of stay (days)	8	Fixed		[25]
Intervention effect				
OR for HF admission: REACH-HF	0.56	Lognormal	2.03	[13]
OR for HF admission: home-based CR	0.70	Lognormal	1.60	Meta-analysis (see Appendix 1)
Duration of treatment effect	4 years	Fixed		Assumption
Costs (per patient)				
Admission HF	£3,873.05	FixedGamma		[29]

Admission other causes	£2,2498	GammaFixed	[20,29]
Admission all cause	£2,901850 <sup>†</sup>	FixedGamma	[20,29]
Ongoing monthly healthcare	£968 <sup>‡</sup>	Fixed	[24,29,41-43]
REACH-HF	£418	Fixed	[13]
Home-based <del>Rehab</del> CR	£477	Fixed	[28]

#### Utilities

Utility for HF patients at baseline	0.736	Fixed	[30]
HF hospital admission decrement	-0.084	Beta	0.006 [30]
Other cause hospital admission decrement	-0.032	Beta	0.005 [30]

#### Assumptions

Usual care was a no CR (either home- or centre-based) approach that included medical management according to national and local guidelines, including specialist HF nurse care.

~~Usual care was assumed to include no use of centre-based CR.~~

Patients can be admitted for HF during any one-month cycle and probability of admission was fixed for all patients at all times regardless of previous admissions.

First and subsequent HF hospitalisations give the same RR of death compared to no hospitalisation.

Other causes hospitalisations don't independently increase risk of death.

Rate of other causes hospitalisations do not change as a result of treatment allocation

The cost and QoL impact of being in any of the post-HF hospitalisation states (from 1 to 38+ months after discharge) were assumed to be the same

\*At baseline i.e. never hospitalised or >38 months since last hospitalisation

‡ Based on data for resource use by type, for people with HF: Comprises £384721 pa for drug costs, £336 pa for A&E attendances, £96101 pa for outpatient appointments and £3020 pa for GP appointments monthly

Formatted: Font: Not Bold

---

<sup>†</sup> We estimate a per month cost for non-HF hospital admission based on a weighted average cost across four common types of non-HF admission (other CVD, renal function, hyperkalaemia and other), using data on proportions of each admission type reported in the EMPHASIS Trial (Zannad [et al \[20\]](#)), combined with unit costs taken from the English National Schedule of Reference Costs 2015/16.

RR: relative risk, OR: odds ratio; HR: hazard ratio

---



Table 2. Results of cost-effectiveness analyses: REACH-HF intervention and home-based CR vs. usual care

	Discounted Costs £, mean (95% CI)	Discounted QALYs mean (95% CI)	ICER (£ per QALY gained) Vs. usual care	% simulations with iNMB > £0
Usual care alone	£ <del>1,505,143,031</del> (£ <del>1,384,412,381</del> to £ <del>1,628,913,549</del> )	<del>4.244</del> .26 (4.05 to 4.43)		
REACH-HF intervention plus usual care	£ <del>1,545,213,157</del> (£ <del>1,424,012,563</del> to £ <del>1,678,014,396</del> )	<del>4.474</del> .56 ( <del>3.833</del> .76 to 4.91)	£ <del>1,721,415</del>	<del>78.77</del> %
Home-based CR plus usual care	£ <del>1,544,413,237</del> (£ <del>1,427,812,598</del> to £ <del>1,678,114,061</del> )	<del>4.404</del> .46 ( <del>3.893</del> .90 to <del>4.774</del> .79)	£ <del>2,413,029</del>	<del>73.75</del> %

## JOURNAL CONTRIBUTOR'S PUBLISHING AGREEMENT

To be completed by the owner of copyright in the Contribution

**Title of Article** : The cost effectiveness of REACH-HF and home-based cardiac rehabilitation in the treatment of heart failure with reduced ejection fraction: a decision model-based analysis

**Journal** : Eur J Prevent Cardiol

**All Author(s)** : Rod S. Taylor, Susannah Sadler, Hasnain M. Dalal, Fiona C. Warren, Kate Jolly, Russell C. Davis, Patrick Doherty, Jackie Miles, Colin Greaves, Jennifer Wingham, Melvyn Hillsdon, Charles Abraham, Julia Frost, Sally

**Corresponding Author** : Prof Rod Taylor

**Corr. Author Address** : University of Exeter Medical School, South Cloisters, St Lukes Campus, Heavitree Road, Exeter, EX1 2LU, England, UK

Please read the full terms and conditions on the following pages, then complete, sign and return all pages of this Agreement to the **Journal's Editorial Office**.

*The author who signs this Agreement certifies that he/she is authorised to sign on behalf of him/herself and in the case of a multi-authored Contribution, on behalf of all other authors of the Contribution. The authors understand that they each have the option of signing and returning a separate copy of this Agreement. This Agreement may be signed and executed by e-mail (a scanned hard copy of the Agreement with your signature on it or a digital original copy with your electronic signature are equally acceptable), by traditional hard copy or by fax.*

### COPYRIGHT ASSIGNMENT

In consideration for publication in the above Journal, you hereby **assign** to the owner(s) (the 'Proprietor') of the Journal identified above (the Journal title subject to verification by SAGE Publishing ('SAGE')) **copyright** in your article ('Article') and the accompanying abstract (all materials collectively referenced as the 'Contribution') prepared by you for the full legal term of copyright and any renewals thereof throughout the world in all languages and in all formats, and through any medium of communication now known or later conceived or developed.

*If you or your funder wish your Contribution to be freely available online to non-subscribers immediately upon publication (gold open access), you can opt for it to be included in SAGE Choice, subject to payment of a publication fee. For further information, please visit [SAGE Choice](#).*

In the event you provide Supplemental Material to the Proprietor, you hereby grant to the Proprietor the **non-exclusive** right and licence to produce, publish and make available and to further sub-license the material, in whole or in part, for the full legal term of copyright and any renewals thereof throughout the world in all languages and in all formats, and through any medium of communication now known or later conceived or developed.

By signing this Contributor Agreement you agree both to the above provisions and to the Terms of the Agreement attached below.

Contributor Signature: Rod Taylor

Digitally signed by Rod Taylor  
Date: 2018.08.23 22:39:34 +01'00'

Date signed: 22nd Nov 2018

You represent that the Contribution is owned by you unless one of the following is checked:

- \*If any author is an employee of the United States Government and prepared the Contribution as part of their official duties, please check here: ☐

US Government Agency Name: \_\_\_\_\_

- If any author prepared the Contribution at the direction of their employer, please have a representative of your employer sign below, and please check here: ☐

Employer Name: \_\_\_\_\_

Authorized Signature: \_\_\_\_\_ Date signed: \_\_\_\_\_

**\*U.S. Government work.** If the Contribution was not prepared as part of the Contributor's official duties, it is not a U.S. Government work. If the Contribution was jointly authored, all the co-authors must have been U.S. Government employees at the time they prepared the Contribution in order for it to be a U.S. Government work; if any co-author was not a U.S. Government employee, then the Contribution is not a U.S. Government work. If the Contribution was prepared under a U.S. Government contract or grant, it is not a U.S. Government work - in such case, copyright is usually owned by the contractor or grantee.

If you are required to submit an addendum by your employer or research funding body, please make your request via email to [contracts@sagepub.co.uk](mailto:contracts@sagepub.co.uk) indicating the name of the Journal and the title of your paper.

## TERMS OF THE AGREEMENT

### **Warranties.**

You warrant to the Proprietor and SAGE that the Contribution is your original work, that you have the full power and authority to enter into this Agreement and to convey the rights granted herein to the Proprietor and to submit the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, either in printed or electronic form, that you have obtained and enclose all necessary permissions for the reproduction of any copyright works not owned by you (including artistic works, e.g. illustrations, photographs, charts, maps, other visual material, etc.) contained in the Contribution and any Supplemental Material you provide and that you have acknowledged the source(s), that the Contribution and any Supplemental Material you provide contain no violation of any existing copyright, other third party rights or any defamatory or untrue statements and do not infringe any rights of others, and you agree to indemnify, defend and hold harmless the Proprietor and SAGE against any claims in respect of any breach of the above warranties. You further agree to be bound by the Terms of the Agreement provided herein as part of this Agreement which outline the circumstances under which the Contribution may be reused.

SAGE for its benefit in accordance with the provisions of the Contracts (Rights of Third Parties) Act 1999 hereby asserts its right to the protection of the above warranties and indemnities.

### **Declaration of Conflicts of Interest.**

You certify that:

1. All forms of financial support, including pharmaceutical company support, are acknowledged in the Contribution.
2. Any commercial or financial involvements that might present an appearance of a conflict of interest related to the Contribution are disclosed in the covering letter accompanying the Contribution and all such potential conflicts of interest will be discussed with the Editor as to whether disclosure of this information with the published Contribution is to be made in the Journal.
3. You have not signed an agreement with any sponsor of the research reported in the Contribution that prevents you from publishing both positive and negative results or that forbids you from publishing this research without the prior approval of the sponsor.
4. You have checked in the manuscript submission guidelines whether this Journal requires a Declaration of Conflicts of Interest and complied with the requirements specified where such a policy exists.

It is not expected that the details of financial arrangements should be disclosed. If the Journal does require a Declaration of Conflicts of Interest and no conflicts of interest are declared, the following will be printed with your Contribution: 'None Declared'.

### **Supplemental Material.**

Supplemental Material includes all material related to the Contribution, but not considered part of the Contribution, provided to the Proprietor by you as the Contributor. Supplemental Material may include but is not limited to datasets, audio-visual interviews including podcasts (audio only) and vodcasts (audio and visual), appendices, and additional text, charts, figures, illustrations, photographs, computer graphics, and film footage. Your grant of a non-exclusive right and licence for these materials to the Proprietor in no way restricts re-publication of Supplemental Material by you or anyone authorised by you.

### **Publishing Ethics & Legal Adherence.**

Contributions found to be infringing this Agreement may be subject to withdrawal from publication (see Termination below) and/or be subject to corrective action. The Proprietor (and/or SAGE if SAGE is different than the Proprietor) reserves the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the Contribution; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.

### **Contributor's Responsibilities with Respect to Third Party Materials.**

You are responsible for: (i) including full attribution for any materials not original to the Contribution; (ii) securing and submitting with the Contribution written permissions for any third party materials allowing publication in all media and all languages throughout the world for the full legal term of copyright; and (iii) making any payments due for such permissions. SAGE is a signatory of the STM Permissions Guidelines, which may be reviewed online.



**Termination.**

The Proprietor and SAGE, together in their absolute discretion, may determine that the Contribution should not be published in the Journal. If in the rare circumstance the decision is made not to publish the Contribution after accepting it for publication, then all rights in the Contribution granted to the Proprietor shall revert to you and this Agreement shall be of no further force and effect, and neither you nor the Proprietor nor SAGE will have any obligation to the other with respect to the Contribution.

**General Provisions.**

This Agreement shall be deemed to be a contract made in England and shall be construed and applied in all respects in accordance with English law and the parties submit and agree to the jurisdiction of the English courts.

This Agreement may be executed in counterparts each of which shall be deemed the original, all of which together shall constitute one and the same Agreement. A faxed copy or other electronic copy shall be deemed as an original. This transaction may be conducted by electronic means and the parties authorize that their electronic signatures act as their legal signatures of this Agreement. This Agreement will be considered signed by a party when their electronic signature is transmitted. Such signature shall be treated in all respects as having the same effect as an original handwritten signature. (You are not required to conduct this transaction by electronic means or use an electronic signature, but if you do so, then you hereby give your authorization pursuant to this paragraph.)

No amendment or modification of any provision of this Agreement shall be valid or binding unless made in writing and signed by all parties.

This Agreement constitutes the entire agreement between the parties with respect to its subject matter, and supersedes all prior and contemporaneous agreements, understandings and representations. The invalidity or unenforceability of any particular provision of this Agreement shall not affect the other provisions, and this Agreement shall be construed in all respects as if any invalid or unenforceable provision were omitted.

If any difference shall arise between you and the Proprietor touching the meaning of this Agreement or the rights and liabilities of the parties thereto, the same shall be referred to the arbitration of two persons (one to be named by each party) or their mutually agreed umpire, in accordance with the provision of the England Arbitration Act 1996 or any amending or substituted statute for the time being in force.

**Consent for Commercial Electronic Messages.**

You hereby provide your express consent for the Proprietor, its affiliates and licensees (expressly including SAGE, where SAGE is not the Proprietor), and their respective designees to contact you in connection with any business communication or other correspondence. The parties agree that such consent may be withdrawn by you at a later time by providing written notice (including by email) to the Proprietor (and/or SAGE if different than the Proprietor). This clause shall survive expiration or earlier termination of this Agreement.

For more information on **copyright and permissions** and **SAGE's publishing policies** (including **Ethics & Responsibility**), please visit the SAGE Journal Author Gateway:

<https://uk.sagepub.com/en-gb/eur/page/journal-author-gateway>

SAGE will provide the Corresponding Author of the Contribution with an electronic copy of the Contribution. For information about **how you may re-use the Contribution**, please consult SAGE Journals Permissions:

<https://uk.sagepub.com/en-gb/eur/journals-permissions>

**All commercial re-use of the published Contribution should be referred to SAGE.**



[Click here to access/download](#)

**Supplemental Data File (.doc, .tif, pdf, etc.)**

Appendix\_revised.docx





[Click here to access/download](#)

**Author Responsibility Form**

[ejpcCEApaper\\_\\_authorship\\_responsibility\\_form.docx](#)

